阳光诺和: 2025年第三次临时股东会会议资料

Core Viewpoint - The company is convening its third extraordinary general meeting of shareholders in 2025 to discuss and vote on key proposals, including a cooperation framework agreement with Dongfang Yanmei (Chengdu) Biotechnology Co., Ltd. and adjustments to daily related party transactions [1][12]. Meeting Procedures - Shareholders and their representatives must arrive 30 minutes before the meeting to sign in and present identification [2]. - The meeting will follow a structured agenda, including the announcement of the number of shareholders present and their voting rights [7]. - Shareholders have the right to speak, inquire, and vote during the meeting, with specific rules governing the conduct of discussions and questions [3][4]. Voting and Decision-Making - Voting will be conducted through both on-site and online methods, with results announced at the end of the meeting [5][6]. - Shareholders must express their opinions on the proposals as either in favor, against, or abstaining, and must sign their ballots [4][5]. Proposed Agreements - The company plans to sign a cooperation framework agreement with Dongfang Yanmei, which includes a procurement cap of CNY 10 million for 2025, CNY 20 million for 2026, and CNY 20 million for 2027 [12][13]. - The agreement aims to leverage both parties' resources for mutual benefit in the pharmaceutical research and development sector [12][17]. Related Party Transactions - The company is adjusting its expected daily related party transaction limits based on operational needs and market pricing [11][12]. - The adjustments are necessary for maintaining normal business operations and are expected to enhance market competitiveness and operational efficiency [12][17]. Financial and Operational Context - The company has established a stable relationship with its related parties, ensuring that these transactions do not adversely affect its independence or financial health [12][17]. - The cooperation with Dongfang Yanmei is positioned as a strategic move to enhance the company's capabilities in clinical trials and related services [12][17].